Related Experiment Videos
Liver resection in advanced hepatocellular carcinoma
V Usatoff1, A M Isla, N A Habib
1Department of Gastrointestinal Surgery, Imperial College of Science and Medicine, Liver Surgery Section, Hammersmith Hospital, London, England.
Hepato-Gastroenterology
|March 28, 2001
Summary
Major liver resection offers survival benefits for advanced fibrolamellar hepatocellular carcinoma and selected noncirrhotic cases. Resection in cirrhotic patients showed limited value, warranting careful consideration.
Area of Science:
- Hepatobiliary Surgery
- Surgical Oncology
- Gastroenterology
Background:
- Advanced hepatocellular carcinoma (HCC) presents significant treatment challenges.
- Major liver resection is a potential curative option for select HCC patients.
- Understanding outcomes in different HCC subtypes is crucial.
Purpose of the Study:
- To evaluate the safety and survival outcomes of major liver resection in advanced HCC.
- To compare results across fibrolamellar, noncirrhotic, and cirrhotic HCC subtypes.
- To determine the role of aggressive resection in advanced HCC management.
Main Methods:
- Retrospective analysis of 19 patients undergoing 24 major liver resections for advanced (Stage IV) HCC.
- Resections included primary tumor (18) and repeat (6) procedures.
- Patient groups comprised those without cirrhosis, with cirrhosis, and with fibrolamellar HCC.
Main Results:
- Overall hospital mortality was 5% (1 patient), with 37% morbidity.
- Fibrolamellar HCC patients demonstrated superior survival (P=0.008).
- Median survival for noncirrhotic HCC was 18 months, versus 9 months for cirrhotic HCC (P=0.24).
Conclusions:
- Aggressive major liver resection with vascular reconstruction is justifiable for advanced fibrolamellar HCC.
- Selected noncirrhotic HCC patients may benefit from aggressive resection.
- Resection in cirrhotic HCC patients appears to have limited value.